OR WAIT null SECS
The year of 2022 will be remembered as one that brought a slew of new advances in cardiovascular disease management and prevention. With approvals, guidelines, and new trial data dominating headlines, several other advances in the field caught the attention of millions and became topics of discussion. To celebrate the end of 2022 and the advances in cardiometabolic health from the past year, our editorial team has created a list of the top 5 most popular pieces of content from 2022.
A new study is sounding the alarm on the potential increase in risk of kidney damage observed with use of rosuvastatin that was not observed with other statin therapies.
Funded by the NIDDKD, results of the study, which assessed the nephrotoxicity of rosuvastatin against atorvastatin using deidentified EHR data from the Optum Labs Data Warehouse, demonstrate use of rosuvastatin was associated with an 8% greater risk of hematuria, a 17% greater risk of proteinuria, and a 15% higher risk of developing kidney failure requiring replacement therapy such as dialysis or transplantation over a median follow-up of 3.1 years compared to use of atorvastatin
Use of dapagliflozin (Farxiga) was associated with an 18% reduction in worsening heart failure or cardiovascular death among patients with heart failure with preserved ejection fraction, according to the results of the phase 3 DELIVER trial.
Less than 3 months after AstraZeneca announced the trial had met its primary endpoint back in May, results of the study build on the evidence from EMPEROR-Preserved and contribute to the idea that the benefits seen in HFpEF could be a class effect for SGLT2 inhibitors.
Results of a study published in the New England Journal of Medicine demonstrate cardiac computed tomography (CT) could provide a safe alternative to catheterization in patients with suspected coronary artery disease.
Aimed at assessing whether cardiac CT could provide a noninvasive alternative to coronary angiography, results of the DISCHARGE trial indicate CT-based examination offered a safe alternative to catherization and could help reduce major procedure-related complications.
The American College of Chest Physicians (CHEST) have released new clinical practice guidance for perioperative management of antithrombotic therapy.
Released on August 11, the guidelines, which include 44 evidence-based recommendations related to perioperative management of antithrombotic therapy, were published with the intent of replacing the organization 2012 guideline on the same topic.
The American College of Cardiology, American Heart Association, and Heart Failure Society of America have released a new joint guideline outlining evidence-based strategies for prevention, diagnosis, and management of heart failure.
Published with the intent of replacing previous guidance published in 2013 and 2017, the guideline includes multiple new additions, including a class 2a recommendation for use of SGLT2 inhibitors in HFpEF and revision to ACC/AHA heart failure stages, and also provides recommendations on managing cardiac amyloidosis and cardio-oncology complications.